Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 4Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Craniopharyngioma 1Cholangiocarcinoma 1Carcinosarcoma 1Brain Neoplasms 1

Interventions

Paclitaxel 6Cyclophosphamide 5pembrolizumab 3Taxes 3Specimen Handling 3Doxorubicin 3Carboplatin 3eribulin 2Trastuzumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sargramostim 1ruxolitinib 1pertuzumab 1onvansertib 1olaparib 1cobimetinib 1atezolizumab 1X-Rays 1Therapeutics 1Radiotherapy 1Radiation 1Panitumumab 1Palliative Care 1Methods 1Magnetic Resonance Spectroscopy 1Letrozole 1Gonadotropin-Releasing Hormone 1Exercise Test 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Inflammatory Breast Neoplasms × cobimetinib × Clear all
NCT03202316 2025-12-16

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
37 enrolled
Breast

Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡